Health Condition 1: null- mitral stenosis patients with sinus rhythm
Conditions
Interventions
Intervention1: ivabradine: ivabradine-5 mg PO bd for 15 days followed by 7.5 mg PO bd for 30 days. It is a drug being used for rate control in CHF and chronic stable angina with proven efficacy. Becau
Sponsors
The Director
Eligibility
Inclusion criteria
Inclusion criteria: 1. Treatment naïve or on pharmacological treatment patients with mitral stenosis (Mitral valve area: 2. Age >18 years of either sex 3. Need for rate control therapy for symptoms 4. Willing to give written informed consent
Exclusion criteria
Exclusion criteria: 1. Atrial fibrillation , Atrial flutter 2. Other significant valvular lesions (More than mild AS/AR/MR) or cardiac conditions ( CAD, active rheumatic carditits or myocarditis, cardiomyopathy) 3. Unable to do TMT/Contraindication for TMT 4. Need for immediate surgical treatment or BMV 5. Presence of significant noncardiac comorbidities- anemia, deranged RFT 6. Pregnancy 7. Congestive heart failure stage IV NYHA; 8. Second/third degree AV block, 9. Resting HR less than or equal to 50 bpm or sick sinus syndrome; 10. Contraindications to atenolol or ivabradine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change from baseline in the total duration of exerciseTimepoint: On day 15 and on day 45 after initiating therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| change from baseline in maximum METs achieved, peak heart rate, time to onset of dyspnea and fatigue, time to limiting dyspnea and fatigue, respiratory rate during 1st minute into recovery, transmitral gradient and pulmonary artery pressuresTimepoint: On day 15 and on day 45 after initiating therapy | — |
Countries
India
Contacts
Public ContactDr Manoj Kumar Rohit
PGIMER
Outcome results
None listed